Novo Nordisk's new CEO said he was confident in the company's pipeline of obesity drugs, but that buying Metsera would allow ...
Novo Nordisk CEO Mike Doustdar tells CNBC he expects to close the company's takeover offer for Metsera. This as the company ...
COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk lowered its full-year profit and sales forecasts again on Wednesday, in an ...
Management reassured investors that there could be substantial value in its lead drug candidate, VK2735.
The financial results show top-line sales growth in the first nine months of the year of 12% to DKK 230 billion ($35.4 ...
The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more heated.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback